Uterine sarcoma Part I—Uterine leiomyosarcoma: The Topic Advisory Group systematic review

详细信息    查看全文

• 作者：Kuo-Chang Wen^a ; ^b ; ¹ ; Huann-Cheng Horng^a ; ^b ; ¹ ; Peng-Hui Wang^a ; ^b ; ^c ; ^{phwang@vghtpe.gov.tw" class="auth_mail" title="E-mail the corresponding author} ; ^{phwang@ym.edu.tw" class="auth_mail" title="E-mail the corresponding author} ; ^{pongpongwang@gmail.com" class="auth_mail" title="E-mail the corresponding author} ; Yi-Jen Chen^a ; ^b ; Ming-Shyen Yen^a ; ^b ; Heung-Tat Ng^b ; ^d ; the Taiwan Association of Gynecology Systematic Review Group^e ; ²Yen-Hou Chang^f ; Yi Chang^f ; Hsiang-Tai Chao^f ; Kuan-Chong Chao^f ; Chi-Mu Chuang^f ; Chi-Hong Ho^f ; Chen-Yu Huang^f ; Zhi-Chen Hung^f ; Ling-Yu Jiang^f ; Hei-Yu Lau^f ; Hsin-Yang Li^f ; Chi-Yao Lin^f ; Chia-Hao Liu^f ; Pi-Lin Sun^f ; Nae-Fang Twu^f ; Hua-Hsi Wu^f ; Hann-Chin Yu^f ; Fong-Yuan Ju^g ; Chih-Ping Tsai^h ; Wen-Hsun Changⁱ ; Yen-Mei Hsuⁱ ; Na-Rong Leeⁱ ; Chih-Yao Chen^j ; Ting-Chen Chang^k ; Wen-Chun Chang^k ; Chii-Hou Chen^k ; Ruey-Jian Chen^k ; Song-Nan Chow^k ; Yih-Ron Lien^k ; Bor-Ching Sheu^k ; Pao-Ling Torng^k ; Men-Luh Yen^k ; Wen-Ling Lee^l ; Kuan-Chin Wang^m ; Chih-Long Changⁿ ; Chih-Ping Chenⁿ ; Jen-Ruei Chenⁿ ; Tze-Chien Chenⁿ ; Jian-Pei Huangⁿ ; Ming-Chao Huangⁿ ; Yeou-Lih Wangⁿ ; Cheng-Chang Chang^o ; Jah-Yao Liu^o ; Her-Young Su^o ; Yu-Chi Wang^o ; Mu-Hsien Yu^o ; Lee-Wen Huang^p ; Kok-Min Seow^p ; Tsung-Hsuan Lai^q ; Fa-Kung Lee^q ; Ching-Hui Chen^r ; Ben-Shian Huang^s ; Sheng-Mou Hsiao^t ; Hsu-Dong Sun^t ; Wen-Yih Wu^t ; Sen-Wen Teng^u ; Kuo-Hu Chen^v ; Jeng-Hsiu Hung^v ; Hung-Cheng Lai^w ; Chiou-Chung Yuan^w ; Ching-Hung Hsieh^x ; Chin-Jung Wang^y ; Shing-Jyh Chang^z ; Man-Jung Hung^aa ; Shih-Tien Hsu^aa ; Yu-Min Ke^aa ; Chien-Hsing Lu^aa ; Lou Sun^aa ; Wei-Chun Chang^ab ; Yao-Ching Hung^ab ; Wu-Chou Lin^ab ; Po-Hui Wang^ac ; Tze-Ho Chen^ad ; Yiu-Tai Li^ae ; Meng-Hsing Wu^af ; Kuo-Feng Huang^ag ; Hung-Chun Fu^ah ; San-Nung Chen^ai ; An-Jen Chiang^ai ; Ju-Yueh Li^ai ; Li-Te Lin^ai ; Hsiao-Wen Tsai^ai ; Kuan-Hao Tsui^ai
• 关键词：diagnosis ; leiomyosarcoma ; treatment ; uterine sarcoma ; uterus
• 刊名：Taiwanese Journal of Obstetrics and Gynecology
• 出版年：2016
• 出版时间：August 2016
• 年：2016
• 卷：55
• 期：4
• 页码：463-471
• 全文大小：482 K

文摘

Uterine sarcomas account for 3–7% of all uterine cancers. Because of their rarity, unknown etiology, and highly divergent genetic aberration, there is a lack of consensus on risk factors for occurrence and predictive poor outcomes as well as optimal therapeutic choices. Tumor types according to the World Health Organization classification include leiomyosarcoma, endometrial stroma sarcoma, and undifferentiated sarcoma. Staging is done using the 2014 Federation International Gynecology and Obstetrics and 2010 American Joint Committee on Cancer tumor, lymph node, and metastases systems. Tumor grade can be classified based on the French Federation of Cancer Centers Sarcoma Group system or the Broder’s system that incorporates tumor differentiation, mitotic count, and tumor necrosis. This review is a series of articles discussing uterine sarcoma, and this is Part I, which focuses on one of the subtypes of uterine sarcomas—uterine leiomyosarcoma. The clinical characteristics, diagnosis, outcome, and recent advances are summarized in this article.